Gossamer Bio's Losses Mount Amid Soaring R&D, Cash Dwindles

Ticker: GOSS · Form: 10-Q · Filed: 2025-11-05T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Pharmaceuticals, Clinical Stage, Cash Burn, Net Loss, R&D Expenses, Liquidity Risk

TL;DR

**GOSS is burning cash fast with massive R&D and no license revenue, making it a high-risk bet for continued operations.**

AI Summary

Gossamer Bio, Inc. (GOSS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $123.1 million, a substantial rise from the $23.5 million loss in the same period of 2024. This was primarily driven by a sharp increase in research and development (R&D) expenses, which climbed to $125.2 million in 2025 from $102.4 million in 2024, and the recognition of $7.5 million in in-process R&D expenses in 2025. Total revenue decreased significantly to $34.7 million for the nine months ended September 30, 2025, down from $105.3 million in 2024, largely due to the absence of revenue from the sale of licenses, which was $88.8 million in 2024. The company's cash and cash equivalents plummeted from $46.1 million at December 31, 2024, to $8.9 million by September 30, 2025, indicating a rapid burn rate. Total assets decreased from $315.3 million to $208.8 million, while total liabilities increased from $285.8 million to $291.2 million, resulting in a negative stockholders' equity of $82.3 million as of September 30, 2025, compared to positive $29.5 million at December 31, 2024. The company acknowledges it will need to raise additional capital to fund future operations.

Why It Matters

Gossamer Bio's escalating losses and dwindling cash reserves signal a critical juncture for investors, raising significant concerns about its long-term viability and ability to fund its clinical programs, particularly seralutinib for pulmonary hypertension. The substantial decrease in total revenue, primarily due to the absence of license sales, highlights a reliance on R&D-heavy operations without a consistent revenue stream. This financial strain could force the company to seek dilutive equity financing or strategic partnerships, impacting existing shareholders. In a competitive biopharmaceutical landscape, a weak financial position can hinder drug development progress and market positioning, potentially affecting future patients and employees.

Risk Assessment

Risk Level: high — The company's accumulated deficit reached $1,391.7 million as of September 30, 2025, and cash and cash equivalents dropped from $46.1 million to $8.9 million in nine months. This rapid cash burn and significant operating losses, coupled with a negative stockholders' equity of $82.3 million, indicate substantial financial instability and a high reliance on future capital raises.

Analyst Insight

Investors should exercise extreme caution and consider divesting GOSS shares due to the rapid cash burn, increasing losses, and negative equity. The company's stated need for additional capital suggests potential future dilution, further eroding shareholder value. Monitor closely for any announcements regarding new financing or strategic partnerships, as these will be critical for its survival.

Financial Highlights

debt To Equity
N/A
revenue
$34.7M
operating Margin
N/A
total Assets
$208.8M
total Debt
$291.2M
net Income
-$123.1M
eps
N/A
gross Margin
N/A
cash Position
$8.9M
revenue Growth
-67.0%

Revenue Breakdown

SegmentRevenueGrowth
Revenue from contracts with collaborators$34.7M109.2%
Revenue from sale of licenses$0.0M-100.0%

Key Numbers

Key Players & Entities

FAQ

What is Gossamer Bio's current financial position regarding cash and liquidity?

As of September 30, 2025, Gossamer Bio had cash and cash equivalents of $8.9 million, a significant decrease from $46.1 million at December 31, 2024. The company also reported a negative stockholders' equity of $82.3 million, indicating a precarious liquidity position.

How have Gossamer Bio's research and development expenses changed?

Gossamer Bio's research and development expenses increased to $125.2 million for the nine months ended September 30, 2025, up from $102.4 million in the same period of 2024. Additionally, the company incurred $7.5 million in in-process research and development expenses in 2025 that were not present in 2024.

What caused the significant decrease in Gossamer Bio's total revenue?

Gossamer Bio's total revenue decreased significantly to $34.7 million for the nine months ended September 30, 2025, from $105.3 million in the prior year. This decline is primarily due to the absence of revenue from the sale of licenses, which accounted for $88.8 million in 2024.

What is Gossamer Bio's accumulated deficit as of September 30, 2025?

As of September 30, 2025, Gossamer Bio's accumulated deficit reached $1,391.7 million, reflecting substantial historical operating losses since its inception.

What is Gossamer Bio's primary drug candidate and its target indication?

Gossamer Bio's primary drug candidate is seralutinib, which is in late-stage clinical development for the treatment of pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD).

Does Gossamer Bio expect to become profitable in the near future?

No, Gossamer Bio expects to continue to incur significant operating losses for the foreseeable future and explicitly states that it may never become profitable. This outlook is consistent with its accumulated deficit of $1,391.7 million.

What are Gossamer Bio's plans for raising additional capital?

Gossamer Bio plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses, and similar arrangements. Management believes it has sufficient working capital for the next 12 months but acknowledges the need for future funding.

What is the risk level associated with investing in Gossamer Bio?

The risk level associated with investing in Gossamer Bio is high. This is evidenced by its significant and increasing net losses, rapid depletion of cash and cash equivalents, negative stockholders' equity, and stated need for substantial future capital raises.

How many shares of common stock did Gossamer Bio have outstanding as of October 31, 2025?

As of October 31, 2025, Gossamer Bio had 231,456,247 shares of common stock ($0.0001 par value) outstanding.

What was the net cash used in operating activities for Gossamer Bio for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Gossamer Bio reported net cash used in operating activities of $122.952 million, a significant increase from the $32.013 million provided by operating activities in the same period of 2024.

Risk Factors

Industry Context

Gossamer Bio operates in the highly competitive and capital-intensive biopharmaceutical industry. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like GOSS focus on developing novel therapeutics, often requiring substantial funding to advance candidates through clinical trials and towards commercialization.

Regulatory Implications

As a biopharmaceutical company, GOSS is subject to rigorous oversight from regulatory bodies such as the FDA. Approval processes for new drugs are lengthy and uncertain, posing a significant risk. Failure to meet regulatory standards or delays in approvals can severely impact product timelines and market access.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

In-process research and development expenses
Costs incurred for research and development activities that have not yet reached technological feasibility and have no alternative future use. These are often recognized as an expense upon acquisition of in-process R&D assets. (A new expense of $7.5 million recognized in the nine months ended September 30, 2025, contributing to the increased net loss.)
Accumulated deficit
The cumulative net losses of a company since its inception, less any net gains. It represents the total losses that have not been offset by profits. (Stood at a significant $1,391.7 million as of September 30, 2025, reflecting the company's history of operating losses.)
Stockholders' equity (deficit)
The residual interest in the assets of an entity after deducting liabilities. A deficit means liabilities exceed assets. (Turned negative to $(82.3) million as of September 30, 2025, indicating financial distress.)
Revenue from contracts with collaborators
Income generated from agreements with other companies for the development or commercialization of products or technologies. (This is the primary source of revenue for GOSS in 2025, showing growth but not enough to offset other financial pressures.)
Convertible senior notes
Debt securities that can be converted into a predetermined amount of the issuer's equity at certain times. (Represents a significant portion of the company's long-term liabilities, totaling $198.3 million as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Gossamer Bio has experienced a dramatic shift in its financial performance. Total revenue has fallen by approximately 67%, largely due to the absence of significant license revenue recognized in 2024. Concurrently, the net loss has widened substantially, increasing by over 400% to $123.1 million, driven by higher R&D expenses and the introduction of in-process R&D charges. The company's balance sheet reflects this deterioration, with a sharp decline in cash and cash equivalents and a move from positive to negative stockholders' equity.

Filing Stats: 4,585 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-11-05 17:23:12

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1 Condensed Consolidated Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Three and Nine Months ended September 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2025 and 2024 (unaudited) 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4

Controls and Procedures

Controls and Procedures 36

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 37 Item 1A

Risk Factors

Risk Factors 37 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3 Defaults Upon Senior Securities 37 Item 4 Mine Safety Disclosures 37 Item 5 Other Information 37 Item 6 Exhibits 37 Exhibit Index 38

Signatures

Signatures 39 3 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) GOSSAMER BIO, INC. Condensed Consolidated Balance Sheets (in thousands, except share and par value amounts) September 30, 2025 December 31, 2024 ASSETS (unaudited) Current assets Cash and cash equivalents $ 8,933 $ 46,074 Marketable securities 171,291 248,444 Receivable from contracts with collaborators 9,243 5,338 Prepaid expenses and other current assets 14,522 10,032 Total current assets 203,989 309,888 Property and equipment, net 70 10 Operating lease right-of-use assets 4,354 5,111 Other assets 407 283 Total assets $ 208,820 $ 315,292 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities Accounts payable $ 1,116 $ 2,319 Accrued research and development expenses 17,736 10,455 Current contract liabilities 23,974 17,050 Accrued expenses and other current liabilities 19,291 15,186 Total current liabilities 62,117 45,010 Long-term convertible senior notes 198,257 197,523 Operating lease liabilities - long-term 3,700 4,398 Long-term contract liabilities 27,079 38,869 Total liabilities 291,153 285,800 Commitments and contingencies (Note 9) Stockholders' equity (deficit) Common stock, $ 0.0001 par value; 700,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 231,306,125 shares issued and outstanding as of September 30, 2025, and 226,604,138 shares issued and outstanding as of December 31, 2024 24 23 Additional paid-in capital 1,314,450 1,296,848 Accumulated deficit ( 1,391,700 ) ( 1,268,568 ) Accumulated other comprehensive income (loss) ( 5,107 ) 1,189 Total stockholders' equity (deficit) ( 82,333 ) 29,492 Total liabilities and stockholders' equity $ 208,820 $ 315,292 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents GOSSAMER BIO, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except sha

View on Read The Filing